Newsroom | 22327 results

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. “This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first twice-yearly HIV prevention option,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development. Our pipeline has become quite mature, with four Arrowhead discovered candidates currently in pivotal Phase 3 s...

FREMONT, Calif.--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company developing treatments that stimulate immune pathways to treat disease, today announced that it will report its second quarter results for 2025 via pre-recorded conference call and webcast on Thursday, August 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link https://www.we...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring its Portfolio Value and Industry Leadership...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced financial results for the second quarter ended June 30, 2025, and provided a business update. “Our team continues to be very disciplined about executing our plans and is making strong progress advancing our clinical stage PBGENE-HBV program whil...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the second quarter of 2025, along with recent product highlights and corporate updates. “Zai Lab is entering a pivotal period – defined by innovation, scale and strong execution,” said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. “We are making meaningful progress throughout our business – expanding patient impact, accelerating global innovation, and opera...

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise Antibodies Ltd. (NASDAQ : IPA) (« IPA » ou la « Société »), une entreprise de biothérapeutique offrant des solutions avancées en matière de biologiques et de découverte de médicaments, a annoncé aujourd’hui la vente de sa filiale basée aux Pays-Bas, ImmunoPrecise Antibodies (Europe) B.V. (« IPA Europe »), à AVS Bio, pour une valeur d’entreprise totale de 12 millions de dollars américains. AVS Bio, une entreprise du portefeuille d’Arlington Capital P...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. “We achieved several important milestones across our pipeline, reflecting our commitment to our mission of powering the immune system to transform lives,” said Marianne De Backer, Chief Executive Officer, Vir Biotechnology. “The initiation of our Phase 1 study of PRO-XTEN™ dual-masked VIR-5525 positions us to potentia...

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2025, and highlighted select corporate progress and achievements. “Innoviva continued to deliver i...

IRVINE, Calif.--(BUSINESS WIRE)--Advanced Sterilization Products (ASP), a global leader in infection prevention and sterilization solutions, is announcing the launch of the BIOTRACE™ Instant Read Steam System, the fastest FDA-cleared steam biological indicator system available in the U.S. Designed with sterile processing departments (SPDs) in mind, the new system delivers a readout in just seven seconds, drastically reducing wait time, minimizing errors, and enhancing clinical workflow efficien...